AZD0120

Phase 3Cell therapy

AstraZeneca

AZD0120 is one of 195 biologic programs targeting AL amyloidosis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

194

Competitors

Pipeline

Status by Indication[3][1]

Indication

AL AmyloidosisActive, not recruiting

Kidney TransplantActive, not recruiting

Autoimmune DiseaseActive, not recruiting

Multiple MyelomaActive, not recruiting

Systemic SclerosisRecruiting

Multiple SclerosisActive, not recruiting

Relapsed/refractory Multiple MyelomaRecruiting

Lupus Erythematosus, SystemicRecruiting

AL AmyloidosisPhase 1/Phase 2

Active, not recruiting

Kidney TransplantPhase 1

Active, not recruiting

Autoimmune DiseasePhase 1

Active, not recruiting

Multiple MyelomaPhase 3

Active, not recruiting

Systemic SclerosisPhase 1

Recruiting

Multiple SclerosisPhase 1

Active, not recruiting

Relapsed/refractory Multiple MyelomaPreclinical

Recruiting

Lupus Erythematosus, SystemicPreclinical

Recruiting

Competition

Competitive Landscape

1135 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

AZD0120

AstraZeneca

Phase 3

2 2

Ninlaro

Takeda

Preclinical

18 3

Prolia

Amgen

Preclinical

5 4

Eliquis

Bristol-Myers Squibb

Preclinical

3 5

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

2 6

Adriamycin

GGynecologic Oncology Group

Preclinical

9 7

Nolvadex

AstraZeneca

Preclinical

1 8

Oncovin

EEastern Cooperative Oncology Group

Preclinical

8 9

Intron a

Systemic Therapy

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1Recruiting

Systemic Sclerosis

NCT07295847

Q2 2028

Phase 1Recruiting

Multiple Myeloma

NCT07073547

Q4 2028

PreclinicalRecruiting

Relapsed/refractory Multiple Myeloma

NCT05850234

Phase 1Recruiting

Multiple Sclerosis

NCT07224373

Q2 2029

PreclinicalRecruiting

Lupus Erythematosus, Systemic

NCT06897930

Clinical

Trials by Indication[1]

Multiple Myeloma2 trials

A Modular, Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120, a Dual-targeting Autologous Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA and CD19 in Participants With Multiple Myeloma (DURGA-2)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 1·NCT07073547·40 enrolled

A Phase III Open-label, Randomised, Multicentre Study Comparing AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CART) Therapy Directed Against BCMA and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma.

Recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT07391657·508 enrolled

Multiple Sclerosis1 trial

An Open-label Study of AZD0120 in Adults With Multiple Sclerosis

Recruiting· AstraZeneca logo

AstraZeneca·Phase 1·NCT07224373·24 enrolled

Kidney Transplant1 trial

CAR-T Therapy Targeting CD19 and BCMA in Highly Sensitized Kidney Transplant Participants

Not yet recruiting·TTongji Hospital·Phase 1·NCT07350837·12 enrolled

Lupus Erythematosus, Systemic1 trial

A Phase 1b/2 Study of AZD0120, a Chimeric Antigen Receptor T-cell (CAR T) Therapy Targeting CD19 and B-cell Maturation Antigen (BCMA) in Subjects With Refractory Systemic Lupus Erythematosus (SLE)

Recruiting· AstraZeneca logo

AstraZeneca·Preclinical·NCT06897930·150 enrolled

AL amyloidosis1 trial

A Phase 1b/2 Study of AZD0120 (Also Known as GC012F), a Chimeric Antigen Receptor T Cell Therapy Targeting CD19 and B Cell Maturation Antigen in Participants With Relapsed or Refractory AL Amyloidosis.

Recruiting· AstraZeneca logo

AstraZeneca·Preclinical·NCT07081646·91 enrolled

2 more indications

Systemic Sclerosis1 trial

A Phase 1b, Open-label, Multi-cohort Study of AZD0120, an Autologous CD19/BCMA Targeting Chimeric Antigen Receptor T-cell, in Adults With Autoimmune Diseases

Recruiting· AstraZeneca logo

AstraZeneca·Phase 1·NCT07295847·27 enrolled

Relapsed/Refractory Multiple Myeloma1 trial

A Phase Ib/II Study of AZD0120, Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR T) Therapy Directed Against CD19 and B-cell Maturation Antigen (BCMA) in Participants With Relapsed/Refractory Multiple Myeloma (DURGA-1)

Recruiting· AstraZeneca logo

AstraZeneca·Preclinical·NCT05850234·182 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for AZD0120. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AZD0120 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AZD0120. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 3[1]
Company: AstraZeneca

AZD0120

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q2 2028

Q4 2028

Q2 2029

Trials by Indication[1]

Multiple Myeloma2 trials

Multiple Sclerosis1 trial

Kidney Transplant1 trial

Lupus Erythematosus, Systemic1 trial

AL amyloidosis1 trial

Systemic Sclerosis1 trial

Relapsed/Refractory Multiple Myeloma1 trial

References

Drug Info

Quick Facts

Related News